Emerging Australian company Recce Pharmaceuticals has appointed an experienced industry executive to lead the translation of its pipeline of anti-infectives.
The company is developing its new class of synthetic anti-infectives with the goal of addressing the increasing risk of antibiotic-resistant superbugs and emerging viral pathogens.
Its pipeline includes three broad-spectrum, synthetic polymer anti-infectives. They are targeting serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, and bacterial and viral infections.
The company says its candidates have the potential to overcome the hypercellular mutation of bacteria and viruses.
The former head of Immunology at CSL Dr Philip Sutton will now oversee the commercialisation of the candidates as Recce Pharmaceuticals' vice president of translational sciences.
Dr Sutton joined the company's scientific advisory committee in August 2020 while he was leading the Mucosal Immunology Group at Murdoch Children’s Research Institute. He has also co-authored 99 peer-reviewed publications.
CEO James Graham said, “Dr Sutton joins us at an exciting time as our clinical programs continue to advance and welcome his contributions to the pipeline development of our new class of anti-infectives.”
Dr Sutton added, “I am delighted to join the Recce team and look forward to the time ahead in addressing the global health problem of antibiotic-resistant superbugs and emerging viral pathogens.”